Jean-René Jourdain

Recent actions taken by European platforms to better coordinate and integrate research activities in radiation protection at the European level





#### **Six European Platforms for a Multidisciplinary Research**



### **The Radiation Protection Platforms**

- Validity and improvement of the radiation protection system for low-dose & low-dose-rate exposures
- Behaviour of radionuclides in the environment, effects to wildlife and impact/risk assessments of radiation to man and environment
- radiological Preparedness for nuclear and emergency response and recovery
- Radiation dosimetry
- Medical applications of ionizing radiation



EUROSAFE



## Support from the EC towards concerted research in RP research

- ALLIANCE, NERIS and MELODI were founded (~2010), and apart from national funding received financial support through Networks of Excellence and preparatory phase projects towards European Joint Programming in H2020
- EURADOS was founded in 1981, received EC funding at the start, but became a self-sustaining eV in 2008
- In Dec 2013, the 4 associations signed a MoU to collaborate in radiation protection research





## Enhancing multidisciplinarity: The European "medical MoU"

- Signed in 2014 between MELODI, EURADOS, ESR (radiology), EANM (nuclear medicine), EFRS (radiography), ESTRO (radiotherapy), EFOMP (medical physics), and notified to the European Commission
- Signatories commit to cooperate on promoting integration and efficiency of European radiation protection research, to maintain and use common infrastructures and to promote scientific E&T
- Signatories set up a Joint Committee and WGs to address this cooperation, and agree to develop mutual information





## Enhancing cooperation with other European platforms

 In the frame of the OPERRA project, contacts were established with SNETP and IGDTP representatives

 MELODI, ALLIANCE, EURADOS and NERIS signed a MoU with NUGENIA on 10 October 2017





#### **MELODI:** an example of a European R&D associative platform



#### **MELODI Membership**



## **MELODI Activities**

- A major activity of MELODI is the establishment and updating of a long-term Strategic Research Agenda (SRA) for research on low-dose risk for radiation protection in Europe (>20 years)
- The SRA is intended to guide the priorities for national and European research programmes, and serve the preparation of European competitive calls
- MELODI WG SRA annually updates the SRA, prepares a statement on the top priorities (prior to calls) and a longterm roadmap





## **MELODI Activities**

- MELODI annual workshops since 2009 (8<sup>th</sup> MELODI workshop in Oxford, UK on 20-22 September 2016; 9<sup>th</sup> MELODI workshop in Paris, France on 10-12 October 2017 in conjunction with the 4<sup>th</sup> ICRP Symposium; 10<sup>th</sup> MELODI workshop in Rovinj, Croatia on 1-5 October 2018)
- MELODI prize rewards a young scientist since 2012
- Scientific opinions (e.g. Chernobyl-related research priorities, childhood leukaemia in the vicinity of NPPs, cancer risk in workers exposed to doses below 100 mSv)
- Organisation of open R&D calls in the frame of the OPERRA and CONCERT EC-supported projects
- Education and training strategy and coordination
- Infrastructures strategy and coordination



### The European Radioecology Alliance

- Founded in 2009 to develop a vision on long-term research needs in radioecology, to foster cooperation and to assure sustainability of radioecology.
- Members of the ALLIANCE
  - 8 founding members in 2009
  - 25 members in January 2017





#### **EURADOS**

Voting Member Status (July 2016)
 67 Voting Members from 30 countries
 Form the General Assembly
 Elects Chair, Vice-Chair, Council

#### EURADOS Board of Officers

Chair:W. Rühm (Helmholtz Munich, Germany)Vice-Chair:F. Vanhavere (SCK-CEN, Belgium)Secretary:JF. Bottollier (IRSN, France)Treasurer:H. Schumacher (PTB, Germany)

#### EURADOS Council

J. Alves, J.F. Bottollier, E. Fantuzzi, P. Fattibene, M.A. Lopez, S. Mayer, S. Miljanic, P. Olko, W. Rühm, H. Schuhmacher, H. Stadtmann, F. Vanhavere







#### **NERIS**

Emergency preparedness, mitigation, post-accident management

- Created in 2010
- Financial support from the European Commission to structure the Platform
- Adoption of legal statutes in May 2012 in Glasgow
- Self-sustainable since 2014
- Currently:
  - 59 organisations from 28 different countries
  - 28 supporting organisations
  - CEPN in charge of the scientific and technical secretariat





## EURAMED

#### Vision:

 Leading European research activities in medical radiation protection and harmonising clinical practice to advance the European radiation protection safety culture in medicine

#### Mission:

- Improving medical care through sustainable research efforts in medical radiation protection
- Identifying common research areas
- Serving as a platform for medical radiation protection research
- Developing aligned approaches and responses to European research calls





#### A Major Tool: the Strategic Research Agenda

- Within the objectives of a platform:
  - Develop a long-term vision on the needs and implementation of activities related to the scope of the platform (decades)
  - Sustainable after FP7 projects
- Appropriate processes for defining short-term priorities and long-term needs are vital
- An adequate Strategic Research Agenda is:
  - NOT: as extensive as possible
  - BETTER: as relevant as possible
    - Usefulness for science and society
    - Shared by stakeholders and researchers
    - Realistic from an operational and scientific point of view





## **Development of SRAs First Version**

Platform	Nbr. of SRA WG Members	Nbr. of Organisations	First Version Released
MELODI	<b>3</b> (Chair: D. Averbeck, FR)	3	11 October 2010
ALLIANCE	<b>27</b> (Chair: T. Hinton, FR)	9	10 August 2012
NERIS	<b>10</b> (plus members of R&D Committee) (Chair of MB : T. Schneider, FR) (Chair of R&D Committee: F. Hardeman, BE)	10	30 March 2012
EURADOS	<b>17</b> (Chair: W. Rühm, DE)	14	2 June 2014
EURAMED	<b>27</b> (Chair: C. Hoeschen, DE)	5	14 April 2015





## **Current Status of SRAs**

Platform	Nbr. of SRA WG Members	Nbr. of Organisations	Latest Update
MELODI	11 (plus 2 external experts/observers) (Chair: S. Bouffler, UK)	13	6 October 2017 (8 <sup>th</sup> Version)
ALLIANCE	<b>27</b> (Chair: J. Garnier-Laplace, FR)	9	5 September 2013 (2 <sup>nd</sup> Version)
NERIS	<b>20</b> (Chair of MB : T. Schneider, FR) (Chair of R&D Committee: J. Camps, BE)	14	8 April 2014 (2 <sup>nd</sup> Version)
EURADOS	17 (Chair: W. Rühm, DE)	14	2 June 2014 (1 <sup>st</sup> Version)
EURAMED	<b>27</b> (Chair: C. Hoeschen, DE)	5	15 February 2017 (1 <sup>st</sup> Version)





## **Current Shape of SRAs**

Platform	Backbone	First-level Division	Second-level Division
MELODI	Three Key Research Questions	Subsections (3 in total)	Research Priorities (38 in total)
ALLIANCE	Three Important Scientific Challenges	Associated Research Lines (15 in total)	
NERIS	Three Research Areas	Key Topics (7 in total)	Subtopics (38 in total)
EURADOS	Five Visions	Challenges (17 in total)	
EURAMED	Five Main Topics	Key Research Questions (19 in total)	





### The example of the MELODI SRA

Backbone	Question 1	Question 2	Question 3		
Three Key Research Questions	Dose/dose-rate dependence of cancer risk?	Non-cancer effects?	Individual radiation sensitivity?		
Subsections (for each key research question)	Basic Mechanisms Health risk evaluation Impact of radiation exposure characteristics				
Research Priorities (here the 5 short- term priorities identified in 2015 from a list of 38 priorities)	<ol> <li>To explore the shape of the dose-response relationship for radiation induced health effects at low doses/dose-rates based on key informative epidemiological studies (including where appropriate, molecular or other biomarkers) for internal and/or external emitters, incorporating detailed dosimetric assessment.</li> <li>To explore and define the role of epigenetic modifications in radiation-induced health effects following exposure to low doses/low dose rates.</li> <li>To identify, develop and validate biomarkers for exposure, early and late effects for cancer or/and non-cancer diseases in relation to low doses/low-dose rates and to integrate them in molecular epidemiological studies.</li> <li>To explore the roles of specific target cells for low dose/dose-rate radiation-induced late developing health effects such as cancers, circulatory diseases and cataract.</li> <li>To understand the potential impact of individual susceptibility on radiation risk using cohorts and/or systems models with variations in sensitivity to low doses of radiation, so that differences in the response pathways can be detected and biomarkers validated.</li> </ol>				





## **Education & Training, Infrastructures**

 MELODI (three priorities), EURADOS (two activities) and EURAMED (two activities) SRAs include priorities/activities related to E&T issues, while this section is being developed in ALLIANCE

 MELODI (two priorities) and EURAMED SRAs comprise a dedicated section on infrastructures ("for quality assurance" in EURAMED), even though the NERIS SRA makes reference twice to research infrastructures along the document, and some EURADOS challenges are undoubtedly related to dosimetry infrastructures

EUROSAFE



## **Some Specificities**

- MELODI and NERIS identified synergistic topics with other radiation protection platforms
- MELODI (five) and NERIS (six) identified short-term priorities or high-priority projects, respectively
- ALLIANCE developed a strategic vision for the next twenty years following six research lines
- NERIS included a section on cross-cutting issues comprising two activities
- EURADOS added a section on harmonisation and practice including five activities





## **Consultation Prior Final Publication**

- The five platforms have submitted their respective SRA to a wide range of scientific communities and stakeholders via questionnaires, e-surveys or workshops
- Comments that were received have been analysed and considered when relevant (feedback provided)
- A transparent and open consultation is essential to ensure the SRA is usefulness for science and society, shared by stakeholders and researchers, and realistic from an operational and scientific perspective

EUROSAFE



Gradual evolution of the Radiation Protection research community in research platforms with support from the EC and the Member States





Preparatory phase projects to support coordination of activities in RP research



Coordination of research through:

- Integration of national and EU research,
- Reach out to new Member states
- Stakeholder involvement
- Identify key research areas
- Include expertise from non-RP research
- Research call organization

OPERRA Task 4.5/ Reaching out to the other technical platforms within EURATOM, e.g. SNE-TP & IDG-TP COMET Task 2.1/ Evolving toward a pan-European Network





## A European Strategy for Radiation Protection Research



## CONCERT EJP

Umbrella structure for radiation protection research in Europe

Co-funding action 70:30 ratio of EC : MS cofund

NERIS

EUROSAFE

- Joint programming
- Open research calls
- Integrative activities

ALLIANCE



MELODI





# The EURATOM integration concept: platforms + projects







#### **The Way Forward**

#### Strategic Research Agendas



EUROSAFE

2017



#### Development of a Joint Roadmap for Radiation Protection Research: CONCERT WP3 task

- 3.1 Integration of SRAs and research priorities from research platforms and national programmes (Lead : BfS)
- 3.2 Joint priority setting (Lead : SCK•CEN)

3.3 **Joint** roadmap development for a long term strategy of radiations protection research in Europe (Lead : MELODI)





#### **Joint Roadmap research and tools**

RPR research includes :

- Basic & applied science
- Supported by state-of-the-art *related* research fields
- Decision-making support
- Dissemination & communication
- Infrastructure, dosimetry & monitoring, E&T





#### Joint roadmap based on (1) sources of exposure

- Human activities related to medical therapy and diagnosis using radionuclides and ionising radiation
- Human activities related to nuclear energy applications and other applications of ionising radiation not related to medical applications
- Human activities related to natural resources, containing naturally occurring radionuclides in which radionuclides are processed neither for their fissile nor their fertile properties
- Natural radiation: telluric and cosmogenic, and natural events leading to radionuclide emissions





#### Joint roadmap based on (2) realistic exposure scenarios

- Exposure of patients
- Exposure of general public & environment to non-medical anthropogenic sources of IR under normal operation
- Planned exposure of workers
- Exposure of general public & environment to legacy
- Exposure of general public & environment to natural radiation
- Exposure of general public, environment & workers to emergency scenarios
- Exposure of general public & environment & workers to malevolent use of IR





#### Strategy towards scenario-based Joint Roadmap





## For each of these exposure scenarios we define in the following order:

#### 1. Questions, e.g.

- What is my risk / benefit?
- What are the confounding factors or other individual sensitivities?
- How does radiation impact the environment and our food chain?
- Is extrapolation of cancer risks from high to low dose correct?
- Are we prepared for impact assessment for accidents scenarios?

#### 2. Needs, e.g.

- Harmonized dosimetry and data management
- Inclusion of IR in the exposome concept

#### 3. R&D challenges, e.g.

- Molecular epidemiology on updated biomarkers linked to Adverse Outcome Pathways, taking into account impact of other stressors leading to similar adverse outcomes
- Radiobiology systems biology to identify mechanisms and biomarkers
- Impact of IR on health (e.g. (pre)pathologic, immune system, microbiome, hereditary)
- Radioecology: Source-term, dynamic transport mechanisms in environment & modeling
- Ecosystem's biology (ecological interactions, biodiversity, food chain,...)





## How to "weigh" priority criteria?

Scenario-dependent STAKEHOLDERS

> Priority setting based on Value for society Science-based Budget available

**GOVERNMENTS / EURATOM** 



**RESEARCHERS** 



#### **Timeline: roadmap preparation**

1<sup>st</sup> joint roadmap version expected end November 2017

 Setup of methodology towards stakeholder consultation on first version (CONCERT WP3 – WP5)

Updated version of roadmap expected in May 2019





Jean-René Jourdain

Recent actions taken by European platforms to better coordinate and integrate research activities in radiation protection at the European level



